Swedencare’s subsidiary Stratford Care USA, today announced that it has executed a long-term agreement with Patterson Veterinary, whereas Patterson acquires the exclusive rights to market and promote the Animal Pharmaceuticals Brand of Dermatology, Dental and Nutritional products for the U.S. Veterinary Market.
Commenting on the new agreement, Jim Van Proosdy, Chief Operations Officer of Stratford Care U.S.A. says: “This is very exciting time for Stratford and our Animal Pharm Brand of products. Our team has been working in partnership with Patterson Veterinary for many years and this agreement both formalizes and ensures our continued growth in the US veterinary market.”
“We are thrilled to have completed this acquisition, and excited to offer Animal Pharmaceuticals products to our Patterson Veterinary and Animal Health International customers,” says Chad Terrell, Vice President of Private Label and Consumer Channel for Patterson’s Animal Health business unit. “Stratford Care USA has a strong reputation as a trusted partner in the animal health industry, which aligns with our purpose, vision and values. We look forward to enhancing our private label portfolio with this exceptional line of Animal Pharmaceuticals products”.
Acquired by Swedencare in 2020, Animal Pharmaceuticals is a quality healthcare range of products launched in 2003 designed to support the health and wellbeing of Dogs and Cats.
“Patterson Veterinary has been instrumental in the growth of the Animal Pharm brand over the years and for some time we have discussed how to develop the partnership best for both parties. The solution is part of our new branding strategy for select partners which will ensure above industry double-digit growth for many years to come. We will be open to these kind of agreements globally when partners show a will and dedication to grow the sales together.” says Håkan Lagerberg, CEO of Swedencare.
